Benitec Biopharma Inc.
Cash Flow Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-45.5M | $-37.9M | $-21.8M | $-19.6M | $-18.2M | $-13.9M | $-8.3M | $2.6M |
| Depreciation & Amortization | $58.0K | $66.0K | $87.0K | $136.0K | $167.0K | $231.0K | $190.0K | $158.0K |
| Depreciation | — | — | — | — | $167.0K | $231.0K | $190.0K | $158.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $26.4M | $17.4M | $830.0K | $452.0K | $870.0K | $634.0K | $237.0K | $672.0K |
| Net Cash from Operating Activities | $-16.5M | $-23.6M | $-19.4M | $-18.0M | $-15.9M | $-12.8M | $-7.5M | $4.8M |
| Investing Activities | ||||||||
| Capital Expenditures | $105.0K | $18.0K | $179.0K | $1.0K | $13.0K | $221.0K | $95.0K | $404.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-105.0K | $-18.0K | $-179.0K | $-1.0K | $-13.0K | $-221.0K | $-94.0K | $-400.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $99.0M | $70.5M | $68.0M | $16.0M | — | $22.5M | $1.8M | — |
| Net Change in Cash | $82.2M | $46.9M | $48.4M | $-1.6M | $-15.7M | $10.0M | — | — |
| Free Cash Flow | $-16.6M | $-23.6M | $-19.6M | $-18.0M | $-15.9M | $-13.1M | $-7.6M | $4.4M |